Intra-Cellular Therapies Inc. CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a 46% increase. CAPLYTA’s strong ...

Northern Biologics Reports Phase I Data Update for MSC-1, an Anti-LIF Antibody ... September 30 th, 2019 12:00 PM - 1:00 PM Session Location: Poster Area (Hall 4), Fira Gran Via, Poster 1196P ...

The ASX200 has been up 0.7% after hitting a new all time intra-day high of 8,462 points. ... ASX Market Update: Index breaks intra-day record | November 25, 2024.